Featured Research

from universities, journals, and other organizations

Younger patients less likely to stick with telemonitoring technology for tracking their heart failure condition

Date:
May 12, 2011
Source:
American Heart Association
Summary:
Younger patients (under age 65) and those with lower health literacy were less likely to stick with telemonitoring technology for tracking their heart failure condition, compared to older patients and those with high health literacy skills, according to new research.

Younger patients (under age 65) and those with lower health literacy were less likely to stick with telemonitoring technology for tracking their heart failure condition, compared to older patients and those with high health literacy skills, according to new research.

Telemonitoring systems use information technology to monitor patients remotely. They are rapidly emerging as a strategy to improve care for patients with heart failure, however, results are mixed. This study finds that patient characteristics are important in determining who will use new technologies and how that may be critical to success.

In the six-month study, researchers evaluated 826 patients enrolled in the telemonitoring arm of the Tele-HF multicenter randomized clinical trial. They examined usage of a telephone system that allowed patients to use the phone's keypad to enter daily information on their symptoms and weight. They found:

  • Eighty-six percent of patients (707 patients) initiated use of the system.
  • Patients who were under age 65 and those who said they were most satisfied with their care were more likely to start using telemonitoring technology.
  • After a week, 90 percent of those who started the system were inputting their weight and symptom data at least three days per week.
  • By the end of the study, more than half (55 percent of patients) continued to participate three days each week.
  • Younger patients (under age 65) and those who had lower health literacy rates (the ability to understand information needed to make informed health decisions) were less likely to stick with the telemonitoring program for six months.

Patients were 19 to 90 years old, average age 61, 44 percent were women, and half were minority.

Understanding factors that influence whether a patient will participate and stay in remote monitoring may help improve the design and therefore the participation in such programs, researchers said.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Younger patients less likely to stick with telemonitoring technology for tracking their heart failure condition." ScienceDaily. ScienceDaily, 12 May 2011. <www.sciencedaily.com/releases/2011/05/110512161925.htm>.
American Heart Association. (2011, May 12). Younger patients less likely to stick with telemonitoring technology for tracking their heart failure condition. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/05/110512161925.htm
American Heart Association. "Younger patients less likely to stick with telemonitoring technology for tracking their heart failure condition." ScienceDaily. www.sciencedaily.com/releases/2011/05/110512161925.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins